Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Urol. doi: /nrurol

Published byVera Makmur Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Urol. doi: /nrurol"— Presentation transcript:

1 Nat. Rev. Urol. doi:10.1038/nrurol.2017.87
Figure 1 Timeline of advances in radiotherapy for the management of RCC Figure 1 | Timeline of advances in radiotherapy for the management of RCC. Reports of SABR targeting primary RCC tumours are shown in blue, developments in radiotherapy technology are shown in grey, advances in surgery are shown in green, and discoveries in basic science are shown in purple. Future and/or ongoing studies are shown in red. CBCT, cone-beam computerized tomography; CN, cytoreductive nephrectomy; PN, partial nephrectomy; RCTs, randomized controlled trials; RN, radical nephrectomy; SABR, stereotactic ablative radiotherapy; SRS, stereotactic radiosurgery; TKI, tyrosine-kinase inhibitor. Siva, S. et al. (2017) Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach Nat. Rev. Urol. doi: /nrurol

Download ppt "Nat. Rev. Urol. doi: /nrurol"

Similar presentations

Tyrosine kinase signalling (review) TGF signalling Notch signalling.

Tyrosine kinase signalling (review) TGF signalling Notch signalling.
Management of T1 Kidney Cancer Laparoscopic Surgery

Management of T1 Kidney Cancer Laparoscopic Surgery
Figure 1. Age Standardized Rate of Oropharyngeal Squamous Cell Carcinoma (OPSCC) in the UK, 2002-2011. Data courtesy of the UK HPV Prevalence Study (1)

Figure 1. Age Standardized Rate of Oropharyngeal Squamous Cell Carcinoma (OPSCC) in the UK, Data courtesy of the UK HPV Prevalence Study (1)
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 2 Recruitment of experts to the Delphi study

Figure 2 Recruitment of experts to the Delphi study
Figure 1 The UMBRELLA SIOP-RTSG 2016 protocol logo

Figure 1 The UMBRELLA SIOP-RTSG 2016 protocol logo
Figure 1 Cellular processes involved in cancer development

Figure 1 Cellular processes involved in cancer development
Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology

Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Figure 1 Current treatments for PNETs

Figure 1 Current treatments for PNETs
Figure 2 Representative images from a right radical

Figure 2 Representative images from a right radical
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Similar presentations

Ads by Google